Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 1, 2005, Pages 153-160

  Sethi, Sanjay ^a,c   Breton, John ^b   Wynne, Brian ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b GLAXOSMITHKLINE   (United States)

^c Medical Research 151   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AUGMENTIN XR; BETA LACTAMASE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; STOMACH DISEASE;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BRONCHITIS, CHRONIC; DOUBLE-BLIND METHOD; FEMALE; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS PARAINFLUENZAE; HUMANS; MALE; MIDDLE AGED; MORAXELLA (BRANHAMELLA) CATARRHALIS; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 11244268729     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.1.153-160.2005     Document Type: Article

References (32)

1. Adam, D. 2000. Short-course antibiotic therapy for infections with a single causative pathogen. J. Intern. Med. Res. 28:13A-24A.
2. Adams, S. G., J. Melo, M. Luther, and A. Anzueto. 2000. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 117:1345-1352.
3. Anthonisen, N. R., J. Mandfreda, C. P. W. Warren, E. S. Hershfield, G. K. M. Harding, and N. A. Nelson. 1987. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 106:196-204.
4. Ball, P., F. Baquero, O. Cars, T. File, J. Garau, K. Klugman, D. E. Low, E. Rubenstein, and R. Wise. 2002. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J. Antimicrob. Chemother. 49:31-40.
5. Ball, P., and B. Make. 1998. Acute exacerbations of chronic bronchitis: an international comparison. Chest 113(Suppl. 3):199s-204s.
6. Campbell, G. D. J. 1999. The role of antimicrobial therapy in acute exacerbations of chronic bronchitis. Am. J. Med. Sci. 318:84-88.
7. Cazzola, M., A. Vinciguerra, G. F. Beghi, G. Paizis, R. Giura, V. Madonni, F. Fiorentini, G. F. Consigli, M. Tonna, A. Casalini, and D. Legnani. 1995. Comparative evaluation of the clinical and microbiological efficacy of coamoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis. J. Chemother. 7:432-441.
8. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12.
9. Craig, W. A., and D. Andes. 1996. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr. Infect. Dis. J. 15:944-948.
10. Dagan, R. 2003. Achieving bacterial eradication using pharmacokinetic/pharmacodynamic principles. Int. J. Infect. Dis. 7(Suppl. 1):S21-S26.
11. Davies, B. I., and F. P. V. Maesen. 1999. Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in-vitro activity. J. Antimicrob. Chemother. 43(Suppl. C): 83-90.
12. Fagon, J., J. Chastre, J. L. Trouillet, Y. Domart, M. C. Dombret, M. Bornet, and C. Gibert. 1990. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Use of the protected specimen brush technique in 54 mechanically ventilated patients. Am. Rev. Respir. Dis. 142:1004-1008.
13. File, T., H. Lode, H. Kurz, and R. Crann. 2003. Comparative efficacy and safety of pharmacokinetically enhanced amoxicillin/clavulanate 2000/125 mg vs amoxicillin/clavulanate 875/125 mg in community-acquired pneumonia (CAP), abstr. B11, p. A370. Abstr. 99th Int. Conf. Am. Thoracic Soc. American Thoracic Society, New York, N.Y.
14. File, T., B. Schlemmer, J. Garau, H. Lode, S. Lynch, C. Young et al. 2000. Gemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. J. Chemother. 12:314-325.
15. Garau, J. 2003. Performance in practice: bacteriological efficacy in patients with drug-resistant Streptococcus pneumoniae. Clin. Microbiol. Infect. 9(Suppl. 1):28.
16. Gotfried, M. H., C. A. DeAbate, C. Fogarty, C. P. Mathew, and W. N. Sokol. 2001. Comparison of 5-day, short-course gatifloxacin therapy with 7-day gatifloxacin therapy and 10-day clarithromycin therapy for acute exacerbation of chronic bronchitis. Clin. Ther. 23:97-107.
17. Grossman, R. F. 1997. Guidelines for the treatment of acute exacerbations of chronic bronchitis. Chest 112(Suppl. 6):310S-313S.
18. Guest, N., and C. E. Langan. 1998. Comparison of the efficacy and safety of a short course of ceftibuten with that of amoxycillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. Int. J. Antimicrob. Agents 10:49-54.
19. Jacobs, M. R., D. Felmingham, P. C. Appelbaum, and R. N. Grüneberg. 2003. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired lower respiratory tract infection to commonly used antimicrobial agents. J. Antimicrob. Chemother. 52:229-246.
20. Kaye, C. M., A. Allen, S. Perry, M. McDonagh, M. Davy, K. Storm, N. Bird, and O. Dewit. 2001. The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate. Clin. Ther. 23:578-584.
21. Marchant, C. D., S. A. Carlin, C. E. Johnson, and P. A. Shurin. 1992. Measuring the comparative efficacy of antibacterial agents for acute otitis media: the 'Pollyanna phenomenon.' J. Pediatr. 120:72-77.
22. Langan, C., B. Clecner, C. M. Cazzola, C. Brambilla, C. Y. Holmes, and H. Staley. 1998. Short-course cefuroxime axetil therapy in the treatment of acute exacerbations of chronic bronchitis. Int. J. Clin. Pract. 52:289-297.
23. Löwdin, E., O. Cars, and I. Odenholt. 2002. Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens including a pharmacokinetically enhanced formulation. Clin. Microbiol. Infect. 8:646-653.
24. National Committee for Clinical Laboratory Standards. 2002. Performance standards for antimicrobial susceptibility testing, 12th informational supplement. Document M100-S11. National Committee for Clinical Laboratory Standards, Wayne, Pa.
25. Nicolson, P., and P. Anderson. 2000. The patient's burden: physical and psychological effects of acute exacerbations of chronic bronchitis. J. Antimicrob. Chemother. 45:25-32.
26. Niederman, M. S., J. S. McCombs, A. N. Unger, A. Kumar, and R. Popovian. 1999. Treatment cost of acute exacerbation of chronic bronchitis. Clin. Ther. 21:576-591.
27. Pauwels, R. A., A. S. Buist, P. M. Calverley, C. R. Jenkins, and S. S. Hurd. 2001. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/W.H.O. Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am. J. Respir. Crit. Care Med. 163:1256-1276.
28. Pfaller, M. A., A. F. Ehrhardt, and R. N. Jones. 2001. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the Respiratory Surveillance Program Study: microbiology for the medical office practice environment. Am. J. Med. 111:4S-12S.
29. Pichichero, M. E. 2000. Short course antibiotic therapy for respiratory infections: a review of the evidence. Pediatr. Infect. Dis. J. 19:929-937.
30. Richard, M.-P., and B. Wynne. 2001. Clinical safety of pharmacokinetically enhanced amoxicillin/clavulanate. Program Abstr 41st Intersci. Conf. Antimicrob. Agents Chemother., abstr. A 952, p. 25. American Society for Microbiology, Washington, D.C.
31. Sethi, S., N. Evans, B. J. B. Grant, and T. F. Murphy. 2002. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N. Engl. J. Med. 347:465-471.
32. Woodnutt, G., and V. Berry. 1999. Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43:29-34.